Table 1.
Baseline Patient Characteristics at ICB Initiation
| Patient Characteristic | n = 2051 |
|---|---|
| Age at start of ICB treatment in years [range] | 63 [40, 90] |
| Sex | |
| Male | 152 (74%) |
| Female | 53 (26%) |
| Race | |
| White | 171 (91%) |
| Asian | 7 (4%) |
| Black or African American | 8 (4%) |
| Other | 2 (1%) |
| ICB drug class | |
| AntiPD1 or AntiPDL1 | 134 (65%) |
| AntiPD1+AntiCTLA4 | 64 (31%) |
| AntiPD1+AntiPDL1 | 7 (4%) |
| Line of ICB treatment 1 | |
| 1st line | 61 (30%) |
| 2nd line | 87 (42%) |
| 3+ line | 57 (28%) |
| Presented with de novo metastatic disease | |
| Yes | 80 (39%) |
| No | 125 (61%) |
| IMDC score at start of ICB treatment | |
| Favorable | 35 (17%) |
| Intermediate | 133 (65%) |
| Poor | 37 (18%) |
| ECOG performance status at start of ICB treatment | |
| 0 | 96 (47%) |
| 1 | 93 (45%) |
| 2 | 16 (8%) |
| Body Mass Index (BMI) | |
| Obese (≥30 kg/m2) | 74 (36%) |
| Overweight (25–30 kg/m2) | 71 (35%) |
| Normal weight (<25 kg/m2) | 60 (29%) |
| Skeletal Muscle Index (SMI) | |
| High SMI | 96 (47%) |
| Low SMI | 109 (53%) |
Abbreviations: ICB=Immune Checkpoint Blockade; ECOG=Eastern Cooperative Oncology Group; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; PD-1=Programmed Death-1; PD-L1=Programmed Death-Ligand 1; CTLA-4=Cytotoxic T-Lymphocyte-Associated Protein-4; SMI=Skeletal Muscle Index; BMI=Body Mass Index.
1
94% of patients who received ICB in the ≥2nd line setting had previously received VEGFR TKI treatment.